Semaglutide fixes clear the path for a critical catalyst year
- The main test is whether new products can offset the active Revlimid patent cliff.
- The company resolved its semaglutide API issues and plans to resume supply in November 2026.
- A June 2026 FDA inspection at the Bachupally biologics facility resulted in a Form 483 with seven observations.
- The Abatacept biosimilar application has an FDA goal date of December 22, 2026.
- Management targets double-digit sales growth and roughly 25 percent EBITDA margins over time.
A fragile bridge after Revlimid
Dr. Reddy's is managing a difficult transition. Generic Revlimid was a major profit source, but its January 2026 patent cliff is actively cutting into North American revenue. The company needs new growth drivers to fill that gap.
The bull case relies on consumer health additions in Europe and complex generic launches. The integration of the acquired nicotine replacement therapy business is largely complete and driving strong European growth. Furthermore, the company has resolved its semaglutide active ingredient scale-up issues and expects to resume supply by November 2026.
The bear case centers on execution risk for upcoming catalysts. The Abatacept biosimilar has a crucial December 2026 FDA goal date. Approval requires a final establishment inspection report for the Bachupally facility, which received a Form 483 with seven observations in June 2026.
Finn's view is balanced. The valuation is favorable, and the recent resolution of semaglutide issues improves the outlook. However, the company remains in a vulnerable transition period until the Abatacept decision is final.
Generics cash, harder launches
Dr. Reddy's makes money by selling generic medicines around the world. It also sells active pharmaceutical ingredients and does some contract manufacturing work for other drug companies.
The traditional model leaned on broad generic scale, especially in North America. The newer strategy shifts toward higher-value areas like consumer health, complex generics, innovative products in emerging markets, and biosimilars. This shift is designed to offset normal generic price decay and sudden patent cliffs.
Management wants double-digit sales growth and about 25 percent EBITDA margins over time. They have also identified a 500 to 600 basis point discretionary cost lever in sales and research spending if margins need defense during the transition.
This model breaks if new launches arrive late, price too low, or fail regulatory inspection. It also struggles if the base U.S. generic business erodes faster than Europe, India, and emerging markets can grow.
What fills the medicine cabinet
Global generics
This is the core business of producing copies of branded drugs. North America remains important, but it is under heavy pressure from Revlimid price erosion.
Lenalidomide
Generic Revlimid has been a major contributor, but the patent cliff is now active and reducing North American sales.
Nicotine replacement therapy
The acquired consumer health business in Europe is largely integrated and driving triple-digit regional growth year-over-year.
Semaglutide
Approved in 10 countries. The company resolved recent manufacturing challenges and plans to resume supply by November 2026.
Abatacept biosimilar
The intravenous version has a December 2026 FDA goal date. Approval relies heavily on clearing regulatory observations at the Bachupally facility.
Rituximab biosimilar
Recently secured U.S. FDA approval. It will be commercialized in the U.S. through a partnership with Fresenius Kabi.
India brands
India is growing double digits, helped by new launches, volume, and selected brand acquisitions like Stugeron.
Where sales come from
The mix reflects general historical trends outlined by management, where North America is the largest segment but also the most exposed to Revlimid declines.
What can still break
Biosimilar approval delays
High impact · High oddsThe Bachupally biologics facility received a Form 483 with seven observations in June 2026. The company is awaiting the final establishment inspection report, which threatens the December 2026 FDA goal date for Abatacept.
Semaglutide final validation
High impact · Medium oddsWhile the active ingredient scale-up issues are resolved, the company still requires successful final validation of the drug product before resuming sales in November 2026.
Revlimid cliff cuts deeper
High impact · High oddsThe January 2026 Revlimid cliff is actively dragging down North America revenue. If the base U.S. business does not stabilize, margin pressure will persist during the transition.
India semaglutide IP loss
Medium impact · Medium oddsDr. Reddy's launched semaglutide in India, but the company is challenging patents in the Delhi High Court. A bad ruling could limit sales or change launch economics in a key early market.
Tariff pressure
Medium impact · Medium oddsPotential U.S. generic or active ingredient tariffs could hurt supply chains and margins. Using a U.S. contract manufacturer for Abatacept helps, but it does not remove the risk for the broader generic portfolio.
In one breath
What does Dr. Reddy's Laboratories do?
Dr. Reddy's sells generic medicines, active pharmaceutical ingredients, consumer health products, and biosimilars. Its main markets include North America, Europe, India, and emerging markets.
Why does Revlimid matter so much for RDY?
Revlimid is the branded drug name for lenalidomide, and Dr. Reddy's generic version was a major profit source. The patent cliff began in January 2026, causing more competition and lower prices in North America.
Is semaglutide already approved for Dr. Reddy's?
Yes, it is approved in 10 countries including Canada and India. After resolving a manufacturing challenge, the company aims to resume supply in November 2026.
What is the next big catalyst for RDY?
The key upcoming catalysts are the targeted November 2026 resumption of semaglutide supply and the December 22, 2026 FDA goal date for the Abatacept biosimilar.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- October 25, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Drug Manufacturers - Specialty & Generic companies
Companies near Dr. Reddy's Laboratories Limited in Finn's Drug Manufacturers - Specialty & Generic industry ranking.

